Exchange: NASDAQ·Updated 07:30 PM EDT

ICLR News

News
all
press releases
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
Here's How Much $1000 Invested In Icon 20 Years Ago Would Be Worth Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 2.59% on an annualized basis producing an average annual return of 11.6%. Currently, Icon has a market capitalization of $12.68 billion. Buyingread more...
Benzinga
ICON Schedules Third Quarter 2026 Earnings Conference Call
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the third quarter 2026 after the market closes on Tuesday, October 27, 2026. The company will hold a conference call and webcast to discuss its financial results...
Business Wire
CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue?
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
ICON plc (NASDAQ: ICLR) (ICON), a world-leading clinical research organisation, today releases its ICON Cares 2025 Report which outlines how the company is delivering on its environmental, social and governance (ESG) priorities with cutting-edge clinical innovation to drive both industry-leading...
Business Wire
Insider Selling: Linda Grais Unloads $138K Of Icon Stock
Linda Grais, Director at Icon (NASDAQ:ICLR), executed a substantial insider sell on August 12, according to an SEC filing. What Happened: Grais opted to sell 841 shares of Icon, according to a Form 4 filing with theread more...
Benzinga
Director Of Icon Makes $138K Sale
Making a noteworthy insider sell on August 12, DR JOHN CLIMAX, Director at Icon (NASDAQ:ICLR), is reported in the latest SEC filing. What Happened: CLIMAX opted to sell 841 shares of Icon, according to a Form 4 filingread more...
Benzinga
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
Zacks
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.
Zacks

Advertisement|Remove ads.